Rare diseases
Investigational molecules
Locations
Kaiser-Friedrich-Ring 71, 65185 Wiesbaden, Germany
AGO Research GmbH demonstrates a concentrated focus on advancing therapeutic strategies for gynecologic malignancies, with particular emphasis on ovarian cancer treatment paradigms. The organization supports research investigating novel approaches to managing advanced-stage ovarian carcinoma, including studies exploring platinum-resistant disease and recurrent epithelial ovarian cancer. Their research portfolio encompasses investigations into optimizing first-line chemotherapy regimens and evaluating innovative combinations of targeted therapies alongside conventional cytotoxic agents.
The sponsor's commitment extends to evaluating both maintenance therapy strategies and combination treatment approaches that integrate PARP inhibitors, anti-angiogenic agents, and immune checkpoint inhibitors with established chemotherapy backbones to improve outcomes in patients with FIGO stage III-IV disease.
AGO Research GmbH runs clinical trials in conditions such as Fallopian tube cancer, Ovarian cancer, Vulval cancer, Malignant peritoneal neoplasm, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Study of Pembrolizumab and Lenvatinib for Patients with Advanced Vulvar Cancer Not Suitable for Surgery or Radiotherapy
GermanyComparison of niraparib alone versus niraparib with bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel
BelgiumStudy on Olaparib and Durvalumab for Patients with Advanced Ovarian Cancer Undergoing Surgery
GermanyStudy on Mirvetuximab Soravtansine and Carboplatin for Patients with Recurrent Ovarian Cancer Eligible for Platinum-Based Chemotherapy
GermanyIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
